Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
03 juin 2024 16h01 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
09 mai 2024 07h30 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
09 mai 2024 07h00 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at ATC 2024
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
28 mars 2024 16h01 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
25 mars 2024 16h56 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 févr. 2024 19h01 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
04 janv. 2024 16h40 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 déc. 2023 18h00 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
29 nov. 2023 16h05 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
09 nov. 2023 16h01 HE
|
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results